Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...

Developed by Ascentage Pharma, olverembatinib is the first China -approved third-generation BCR:ABL1 inhibitor, currently being jointly commercialized in China by Ascentage Pharma and Innovent ...

The opioid addiction treatment market will be worth $2.4bn by 2033, driven by diagnoses in the eight major world markets.

Chase Mining Corporation Limited (AU:GCM) has released an update. Chase Mining Corporation Limited has acquired an innovative technology to ...

Their work can help to lower the ... The Evolution of Green Energy Technology: Developing Three-Dimensional Smart Energy Devices With Radiant Cooling and Solar Absorption Oct. 25, 2024 — - DGIST ...

A major challenge with these medical apps is the lack of guidance on established regulatory pathways, especially for wearable medical technologies. Innovators wanting to market their products must ...

Oct. 30, 2024 — Research provides a deeper understanding of precisely what is happening in organic solar cells as light is converted into electricity. Researchers developed a new method which ...

Based on RNA technology, ICON’s new assay offers huge improvements on how CML is monitored ... NGS assay known as Dup-Seq BCR::ABL1. This innovative assay enables the identification of both ...

The McGraw Center is at the heart of efforts to integrate innovative educational technologies into the academic experience. The center encourages the exploration of new media and digital tools in and ...

The company intends to list the token on a number of other exchanges. This innovative tokenization initiative aims to revolutionize the mining sector by providing a new financing model for mining ...

Join the CML Book Club! The CTV Morning Live hosts will share a new title each month. Read along, share your thoughts, and recommend your favourite books. The CML Book Club’s first selection is ...